Beta2-mimetic and Central Nervous System

Study Overview
=================
Brief Summary
-----------------
Beta2-mimetics such as Salbutamol have been shown to have ergogenic effects. Acute and chronic inhaled or oral doses of Salbutamol have been shown to increase whole body exercise and muscle performances. The underlying mechanisms are however unclear. Some data suggest that Salbutamol may have some effects on the central nervous system which may explain the improved exercise and neuromuscular performances. The present study aims to assess the effects of acite inhaled or oral Salbutamol intake on the neuromuscular system by using neurostimulation techniques and magnetic resonance imaging.

Detailed Description
-----------------
The effects of Salbutamol intake will be assessed by using transcranial magnetic stimulation on one hand and magnetic resonance imaging on the other hand. Maximal voluntary activation and cerebral activation will be measured during motor tasks performed until exhaustion after acute inhaled slabutamol intake, acture oral salbutamol intake or oral placebo intake.

Official Title
-----------------
Beta2-mimetic and Central Nervous System: Effects of Salbutamol on Cortical Excitability and Cerebral Activation

Conditions
-----------------
Adrenergic Beta-2 Agonist Effect, Albuterol Effect

Intervention / Treatment
-----------------
* Drug: Salbutamol
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy subjects without respiratory and cordiovascular diseases Male Age between 18 and 35 Trained subjects (>6 hours of physical activity per week) Non- or ex-smoker (smoking cessation since at least 1 year) Exclusion Criteria: Respiratory, cardiovascular and metabolic diseases Neuromuscular diseases thyrotoxicosis, or diabetes treated with insulin alcoholism MRI contraindication TMS contraindication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Inhaled Salbutamol<br>Acute inhalation of 800 microgram Salbutamol | Drug: Salbutamol<br>* Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.<br>* Other names: Albuterol;|
| Experimental: Oral Salbutamol<br>Acute oral intake of 4 mg Salbutamol | Drug: Salbutamol<br>* Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.<br>* Other names: Albuterol;|
| Placebo Comparator: Placebo<br>Acute oral intake of a placebo | Drug: Placebo<br>* Acute oral intake of a placebo drug<br>* Other names: Albuterol;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximal voluntary activation | Measurement performed by using transcranial magnetic stimulation, superimposed on submaximal and maximal quadricep contractions | Measured immediatly after treatment intake (within 1 h) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cortical activation | Measurement performed by using magnetic resonance imaging and the intensity of the BOLD signal in response to a motor task. | Measured immediatly after treatment intake (within 1 h) | 
| Exercise endurance | Time to exhaustion during the exercise muscle test. | Measured immediatly after treatment intake (within 1 h) |